Sens. Jeanne Shaheen (D-N.H.) and Susan Collins (R-Maine) are both leaving Congress at the end of the year; Shaheen is retiring and Collins lost her re-election bid to Democrat Troy Jackson.
The legislation, which has 28 co-sponsors divided equally between the parties, would cap out-of-pocket costs for insulin at $35 for people with commercial insurance, building off a similar provision for people on Medicare that passed in former President Biden’s Inflation Reduction Act in 2022. It would also create a pilot program in 10 states to cap costs for uninsured people, among other provisions.
The bill cleared the Senate Committee on Health, Education, Labor and Pensions in July, putting it closer than ever to final passage.
Lawmakers have discussed the idea of an insulin cap for years but haven’t been able to get legislation over the finish line because of GOP resistance to the government setting prices.
Shaheen argued the midterm election results are a clear sign that voters want lawmakers to pass legislation that makes life more affordable.
“Voters sent a clear message this election that Congress needs to take urgent action to lower costs for American families,” Shaheen said in a statement this week. “With my INSULIN Act, we have a bipartisan opportunity right in front of us to deliver meaningful relief by capping monthly insulin costs at just $35.”
The most likely path forward would be including the measure as part of a year-end spending bill, but it could also be attached to the must-pass defense policy and spending authorization legislation.
A key measure in Biden’s Inflation Reduction Act capped insulin prices to $35 per month for seniors on Medicare. That legislation passed without any GOP support.
Since then, many pharmaceutical companies have voluntarily reduced their prices, but Collins and Shaheen have said it’s not enough.
The cost of insulin has been a barrier to care for many Americans. A monthly cap on patient cost sharing would make the drug cheaper for patients and improve access, but it wouldn’t directly address the underlying price of insulin.
Last week, advocacy organizations, including the National Kidney Foundation and American Diabetes Association, sent letters to the White House and congressional leadership of both parties, urging them to support and immediately pass the legislation.